Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2 13Phase NA 11Phase 4 4Phase EARLY_PHASE1 1Phase 2/3 1

Status

Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1

Conditions

Neoplasms 2Nausea 2Vomiting 1Thyroid Neoplasms 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × OTHER × Ondansetron × Clear all
NCT06697782 2025-01-22

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 4 Completed
600 enrolled
Head & Neck

Thyroid Neoplasms

NCT00588835 2020-11-30

ACE

Radboud University Medical Center

Phase 4 Terminated
20 enrolled

Nausea, Neoplasms

NCT01913990 2017-01-30

ER11-02

Ottawa Hospital Research Institute

Phase 4 Unknown
323 enrolled

Nausea, Vomiting

NCT01896440 2013-10-08

Heart Safety Study of Ondansetron in Children Receiving Chemotherapy

University of Oklahoma

Phase 4 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡